stockrow
Saturday 7 November 2026
Export PMCB’s income statement to Excel — free account
Nuvilex Inc.
PMCB Healthcare Biotechnology
- EPS
- +56.1%
- Free cash flow
- +60.8%
Quarter to July 2026, against a year earlier
0.37
0.01
−2.63%
Follow PMCB
Alert me
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
40.29 | 45.28 | 12.33 | 14.60 |
+8 more quarters Free account |
Net Debt/EBITDA |
30.31 | 14.77 | 9.70 | 11.34 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.14 | 0.29 | 0.51 | 0.12 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.07) | (0.17) | (0.08) | (0.14) | |
Cash per Share |
2.84 | 4.43 | 2.22 | 2.30 | |
Shareholders Equity per Share |
2.56 | 3.97 | 4.11 | 5.18 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.56 | 3.97 | 4.11 | 5.18 | |
Free Cash Flow |
(0.78) | (1.39) | (0.79) | (0.98) | |
Working Capital |
30.21 | 36.59 | 19.02 | 21.45 | |
Net Current Asset Value |
21.77 | 23.96 | 2.94 | 2.28 | |
| Other line items | |||||
Quick Ratio |
40.25 | 45.16 | 12.24 | 13.06 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.07) | (0.17) | (0.08) | (0.14) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
2.06 | — | — | — | |
Average Payables |
0.43 | 0.34 | 0.84 | 0.68 | |
Average Assets |
40.91 | 50.96 | 49.85 | 55.54 | |
Average Common Equity |
35.55 | 42.59 | 39.18 | 39.34 |
Columns are period end dates · fundamentals updated 26 Oct 2026